General Information of Drug (ID: DMT893N)

Drug Name
N5-(1-iminobutyl)-L-ornithine Drug Info
Synonyms
CHEMBL442896; N5-(1-iminobutyl)-L-ornithine; Ethyl-L-NIO; AC1NRDHJ; (2S)-2-amino-5-(1-aminobutylideneamino)pentanoic acid; BDBM152700; BDBM50255074; ZINC12503853; (S)-2-Amino-5-butyrimidoylamino-pentanoic acid; (S)-2-Amino-5-butyrimidamidopentanoic acid (9)
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5289555
TTD Drug ID
DMT893N

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
SD-6010 DM9DEYL Osteoarthritis FA00-FA05 Phase 3 [3]
MPL-S DMNDCFY Endotoxic shock 1G41 Phase 3 [4]
Pimagedine HCl DMPWH30 Diabetic kidney disease GB61.Z Phase 2/3 [5]
GW274150 DMZMCB1 Asthma CA23 Phase 2 [6]
BXT-51072 DMD8GNB Cardiovascular disease BA00-BE2Z Phase 2 [7]
HP-228 DMNZ35F Postoperative pain MG30-MG3Z Phase 2 [8]
CR-3294 DMHJEZS Diarrhea ME05.1 Phase 2 [9]
KD-7040 DME1WV2 Pain MG30-MG3Z Phase 2 [10]
LT-1951 DM5N04G Coronary artery disease BA80 Phase 1/2 [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tilarginine acetate DMZBGI8 Myocardial infarction BA41-BA43 Phase 3 [12]
L-NAME DM01SR6 Hypertension BA00-BA04 Phase 2 [13]
ACCLAIM DM0FGDO Angina pectoris BA40 Phase 2 [14]
VAS-203 DMKU93J Brain injury NA07.Z Phase 2 [15]
MTR105 DMT0K4F Hypotension BA20-BA21 Phase 2 [16]
Autologous cell based gene therapy DMQA1VT Pulmonary hypertension BB01 Phase 1 [17]
L-NIL DM6Y49D N. A. N. A. Terminated [18]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [19]
2-Methyl-2,4-Pentanediol DMD45CU Discovery agent N.A. Investigative [19]
Heme DMGC287 Discovery agent N.A. Investigative [20]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [21]
NXN-462 DMWVBS2 Headache 8A80-8A84 Phase 2 [22]
L-NIL DM6Y49D N. A. N. A. Terminated [18]
Alpha-D-Mannose DMF5DLW Discovery agent N.A. Investigative [19]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [19]
Flavin-Adenine Dinucleotide DM5S4GK Discovery agent N.A. Investigative [19]
Heme DMGC287 Discovery agent N.A. Investigative [20]
Formic Acid DMNFZC6 Discovery agent N.A. Investigative [19]
2'-Monophosphoadenosine 5'-Diphosphoribose DME9S8M Discovery agent N.A. Investigative [19]
6-isobutyl-4-methylpyridin-2-amine DM2XB68 Discovery agent N.A. Investigative [23]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Nitric-oxide synthase brain (NOS1) TTZUFI5 NOS1_HUMAN Inhibitor [1]
Nitric-oxide synthase endothelial (NOS3) TTCM4B3 NOS3_HUMAN Inhibitor [1]
Nitric-oxide synthase inducible (NOS2) TTF10I9 NOS2_HUMAN Inhibitor [1]

References

1 Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
2 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
3 A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95.
4 Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun. 1997 Aug;65(8):3239-47.
5 Nitric oxide associated with iNOS expression inhibits acetylcholinesterase activity and induces memory impairment during acute hypobaric hypoxia. Brain Res. 2008 Sep 16;1230:138-49.
6 GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int. 2003 Mar;63(3):853-65.
7 Shear stress induces iNOS expression in cultured smooth muscle cells: role of oxidative stress. Am J Physiol Cell Physiol. 2000 Dec;279(6):C1880-8.
8 HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro. J Pharmacol Exp Ther. 1995 Nov;275(2):584-91.
9 Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. Cancer Chemother Pharmacol. 2010 October; 66(5): 819-827.
10 WO patent application no. 2014,0214,08, Method for treating cancer by anticancer agent co-administration.
11 Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation. 2003 May 27;107(20):2607-14.
12 Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007 Apr 18;297(15):1657-66.
13 Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection. Vascul Pharmacol. 2009 Oct;51(4):253-61.
14 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
15 Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). J Neurotrauma. 2014 Oct 1;31(19):1599-606.
16 Nitric oxide synthase inhibitor (MTR-105) during open-heart surgery. A pilot double-blind placebo-controlled study of hemodynamic effects and safety. Cardiology. 2008;111(3):181-7.
17 Feasibility of using autologous transplantation to evaluate hematopoietic stem cell-based gene therapy strategies in transgenic mouse models of human disease. Mol Ther. 2002 Sep;6(3):422-8.
18 Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43.
19 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
20 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
21 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
22 ClinicalTrials.gov (NCT01748877) Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia. U.S. National Institutes of Health.
23 Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.